Posterior Reversible Encephalopathy Syndrome In Leukemic Children: A Sensitive Issue

ISSN: 2212-3911 (Online)
ISSN: 1574-8863 (Print)


Volume 9, 3 Issues, 2014


Download PDF Flyer




Current Drug Safety

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Dr. Seetal Dodd
University of Melbourne
Geelong, 3220
Australia


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


Posterior Reversible Encephalopathy Syndrome In Leukemic Children: A Sensitive Issue

Author(s): Wala Ben Kridis, Moez Mdhaffer, Yosr Hentati, Fatma Kammoun, Abir Milad, Sondes Haddar, Khaireddine Ben Mahfoudh, Chahinez Triki and Moez Elloumi

Affiliation: Department of Hematology Hedi Chaker Hospital Sfax 3029 Tunisia

Abstract

Posterior reversible encephalopathy syndrome (PRES) is an acute central nervous system disorder characterized by reversible brain vasogenic edema.

We report here a new case of a nine-year-old boy with B-cell acute lymphoblastic leukemia (B-ALL) who developed PRES secondary to induction chemotherapy including dexamethasone (dexamethasone®), vincristine (oncovin®), daunorubicin (adriblastine®) and intrathecal injection. Cerebral magnetic resonance imaging (MRI) showed high signal intensity on T2 at cortical and sub cortical region of parieto-frontal and parieto-occipital lobes. The patient was put under sodium valproate (depakine®) and we decided to continue dexamethasone (dexamethasone®) and daunorubicin (adriblastine®) injection. The MRI, after four weeks, was normal. So, we resumed vincristine (oncovin®) and we started L-asparaginase injections. Then, the outcome was favorable.

The treatment of PRES is based on the withdrawal of the triggering factor to avoid the risk of irreversible lesions. But, given the severity of leukemia the stopping of chemotherapy is difficult because of the risk of disease progression


Keywords: Chemotherapy, diagnosis, etiopathogeny, leukemia, PRES, treatment

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 9
First Page: 1
Last Page: 5
Page Count: 5
DOI: 10.2174/1574886309666140610160851
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science